RC108 and Furmonertinib for first-line treatment of EGFR-mutated and MET-positive NSCLC
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether a combination of two drugs, RC108 and Furmonertinib, can help people with non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutation and MET positivity) and cannot be removed by surgery. It is for people who have not yet received treatment for their advanced or metastatic cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer (NSCLC) that is advanced (stage IIIB/IIIC or stage IV) and cannot be surgically removed.
- You cannot have received any previous systemic treatment (like chemotherapy or targeted therapy) for your advanced or metastatic cancer.
- Your tumor must have both an EGFR mutation (exon 19 deletion or L858R) and be MET-positive.
- You must be between 18 and 75 years old.
- Your health status should allow you to perform daily activities (ECOG score 0 or 1).
- You must be willing to provide a tumor tissue sample for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a targeted pill (furmonertinib), chemotherapy into the spinal fluid, and precise radiation for people with a specific type of lung cancer (EGFR-mutant adenocarcinoma) that has spread to both the brain and the lining around the brain. The goal is to see if this combination can better control the cancer and improve symptoms.
This Phase 2 trial studies furmonertinib alone or with other treatment options to control advanced lung cancer that has specific EGFR gene changes. It may help by targeting the cancer-driving EGFR mutation, especially in people whose mutation is confirmed by a ctDNA blood test.
This trial tests whether taking furmonertinib before surgery can help shrink tumors in people with early-stage EGFR-mutant lung cancer. It aims to improve surgical outcomes and long-term results.
This trial tests whether a targeted pill (furmonertinib) combined with local treatments like radiation or heat/cold to destroy the tumor can help people with early-stage lung cancer that has specific genetic changes (EGFR mutations). It aims to control the cancer without surgery.
This trial tests a combination of two targeted drugs, vebreltinib and furmonertinib, for people with advanced non-small cell lung cancer that has an EGFR mutation and high levels of a protein called PD-L1. It may be an option for those who have not yet had treatment for advanced disease.
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.